Modified Widal test using 2-mercaptoethanol for detecting anti-salmonella IgM in febrile patients

R. K. Agarwal¹, B. Chatterjee², G. Mittal³, T. Bhatla⁴, Ankit Agarwal⁵

¹Professor, ²Associate Professor, ³MBBS Intern, Dept. of Microbiology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, ⁴Associate Professor, Dept. of Anesthesiology, All-India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

*Corresponding Author:
Email: doctorbiswaroopchatterjee@gmail.com

Received: 27th April, 2018
Accepted: 30th May, 2018

Abstract
Introduction: Despite limitations, the Widal test is widely used in resource-constrained settings because it is fast, inexpensive and user-friendly. Therefore, efforts continue to improve its diagnostic utility. Aims: Using 2-mercaptoethanol (2-ME) to detect the IgM fraction of total agglutinins detected by the Widal test in the serum of febrile patients.

Materials and Methods: Single serum specimens were collected from 333 patients presenting to our hospital with fever. One aliquot of serum was tested by standard Widal test; a positive result was defined as simultaneous elevation of ‘O’ and ‘H’ titres to 1:80 or above. A second aliquot was simultaneously tested by a modified Widal test in which serum was diluted in isotonic saline with added 2-ME (0.12M) instead of in plain isotonic saline. Differences in titre between the two versions of Widal test were noted. A four-fold or greater reduction in titre upon testing with 2-ME, was considered evidence of specific IgM.

Results: Standard Widal test was positive in 55 (16.5%) out of 333 patients. A ≥4-fold reduction of ‘O’ titre in modified Widal test was found in 38 (69.1%) out of 55 cases, indicating the presence of specific IgM. A similar reduction of ‘H’ titre was seen in only 6 (11%) out of 55 cases.

Conclusion: Simultaneous use of standard Widal test and modified Widal test with 2-ME allows the detection of specific IgM at a low cost. This can increase the diagnostic utility of the Widal test.

Keywords: Acute febrile illness, Typhoid fever, Serology, IgM, Laboratory diagnosis.

Introduction
Typhoid fever, caused by Salmonella enterica subsp. enterica Serotype Typhi (commonly known as Salmonella Typhi) is one of the commonest infectious diseases in the developing world.¹,² Its annual incidence in India has been estimated to be 760/100,000,³ and up to 10% of all children living in urban slums can end up with the disease.⁴ The problem has been aggravated by the emergence of resistance to multiple antimicrobials.⁵

Laboratory diagnostic modalities include culture, nucleic acid amplification, and serological testing.⁵ Definitive diagnosis requires isolation of the organism from blood, bone marrow or other specimens. However, facilities for bacterial culture are not always available or affordable. Therefore, the need for a quick, affordable and user-friendly test is keenly felt. The Widal test, which was developed by George Ferdinand Widal in 1896,⁶ does fulfill these criteria. The principle of the test is the visible agglutination of Salmonella antigen by specific antibody in the patient’s serum.

Though the Widal test has been in use for more than a century, its value in the diagnosis of enteric fever is still debated.⁷ First of all, agglutinins take around a week to appear after the onset of illness in immunologically naïve individuals; therefore, the test is of practically no use in the first week of fever. Secondly, people who have been infected or immunized in the past, may develop an anamnestic response during an unrelated illness. A false-positive Widal test is known to occur in chronic liver disease, rheumatoid arthritis, myeloma, nephrotic syndrome and in febrile illnesses such as typhus and malaria.⁸,⁹ On the other hand, the antibody response may be dampened in relapse and after antimicrobial treatment; this may lead to false-negative Widal results. Since enteric fever is endemic in India, many healthy individuals have circulating antibodies due to repeated exposure to typhoid bacilli. A single Widal test is therefore considered to be of little use in diagnosis. A four-fold or greater rise in titre when the Widal test is repeated 7-10 days after the first, is considered diagnostic; however, it is seldom possible to wait that long for a definitive diagnosis.

A modified Widal test¹⁰-¹³ is available on which serum is first treated with 2-mercaptoethanol (2-ME) to inactivate IgM antibodies. A four-fold or greater fall in antibody titre after 2-ME treatment indicates the presence of IgM which is considered a marker of current or recent infection. The present study was therefore undertaken to look at the occurrence of specific IgM antibodies, as inferred from the reduction of ‘O’ and ‘H’ titres in the modified Widal test, in the sera of febrile patients testing positive by the standard Widal test.
Materials and Methods

The study was conducted on serum specimens referred to our laboratory for the standard Widal test. These non-replicate specimens had been taken from 333 patients presenting with acute febrile illness during the two-month period from June 1, 2015 to July 31, 2015. For the purpose of this study, patient identity was kept anonymous. Standard Widal test was performed in Felix and Dreyer’s tubes by standard technique.14

Modified Widal test with 2-mercaptoethanol (2-ME): This test was done exactly the same way as the standard Widal test except that serum dilutions were made in isotonic saline to which 2-ME had been added to a final concentration of 0.12M (made by adding 9.37 ml of 2-ME to 1000 ml of isotonic saline). Four-fold or greater reduction in titre compared to the standard test was considered indicative of specific IgM antibodies and counted as a positive result in the modified Widal test with 2-ME.

Salmonella antigen was obtained commercially from Span Diagnostics, India for both versions of the test.

Results

Fifty-five (16.5%) of 333 serum specimens from febrile patients had both ‘O’ and ‘H’ titres ≥ 1:80 in the standard Widal test. Young adults in the age group of 15-29 years were affected most often with no significant sex difference (Table 1).

Antibody titres in the standard Widal test are presented in Table 2. Most patients had titres of 1:80 or 1:160; only a few had titres of ≥1:320.

The modified Widal test with 2-ME led to a ≥4-fold fall in ‘O’ titre in 38 (69%) specimens, indicating an important contribution of IgM to the ‘O’ antibody response (Table 3). In contrast, a ≥4-fold fall in ‘H’ antibody titre was seen in only 6 (11%) of specimens, indicating that only a few subjects had a significant IgM response to ‘H’ antigens (Table 4).

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Sex</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-29 years</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>30-44 years</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>&gt;45 years</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
<td>26</td>
</tr>
</tbody>
</table>

Table 2: Titres of ‘O’ and ‘H’ antibodies in standard Widal test

Table 3: Reduction in titre of ‘O’ antibody in 2-mercaptoethanol test

Table 4: Reduction in titre of ‘H’ antibody in 2-mercaptoethanol test

Discussion

‘O’ agglutinin titres decreased four-fold or more in 69% of our specimens after 2-ME treatment. This is similar to the figure reported by Sendil et al. in a recent study on the modified Widal test using 2-ME.13 It is noteworthy that although ‘O’ titre underwent a fourfold or greater decrease in the 2-ME Widal test in the majority of our specimens, they never became undetectable, thus indicating the presence of other immunoglobulin isotypes such as IgG and possibly IgA. This is supported by Chernokhivostova et al. who demonstrated that the ‘O’ antibody response after natural infection is comprised of IgM, IgG and IgA, while the response to artificial immunization with killed cells is comprised exclusively of IgM.15

Only 10% of our specimens demonstrated a four-fold or greater reduction in ‘H’ antibody titre after 2-ME treatment. This is in sharp contrast to the findings of several recent publications.10-13 It is possible that most of our subjects had been exposed to Salmonella Typhi in the past and, therefore, launched a IgG-dominant secondary antibody response during their current illness.

Our study had one important difference in design compared to other studies on the modified Widal test using 2-ME. While the other studies looked at specimens from patients with culture-documented typhoid fever only, we chose to test specimens from all febrile patients with a clinical suspicion of typhoid fever. We consider our decision justifiable because blood-cultures are positive in an average of only 61% of patients of typhoid fever, as shown in a recent systematic literature review.16 In fact, no diagnostic test for typhoid fever has proved to be a satisfactory ‘gold-
standard' for evaluating the performance of newer tests, and this has led to an increasing reliance on standardized composite references based on Bayesian statistics.17

Conclusion

The modified Widal test with 2-mercaptoethanol demonstrated a strong IgM response to Salmonella Typhi ‘O’ antigen in more than two-thirds of our specimens that had ‘O’ and ‘H’ titres ≥1:80 in the Standard Widal test. Since IgM is considered an indicator of current or recent infection, this low-cost modification of the Widal test has the potential to increase the specificity and acceptability of this widely used investigation.

References


How to cite this article: Agarwal RK, Chatterjee B, Mittal G, Bhatla T, Áagarwal A. Modified Widal test using 2-mercaptoethanol for detecting anti-salmonella IgM in febrile patients. Indian J Microbiol Res. 2018;5(3):355-357.